Biobetter Versions of Recombinant Human IFN-α2b for the Treatment of Viral Infections

Autores
Mufarrege, Eduardo Federico; Peña, Lucía Carolina; Echeverrigaray, Marina
Año de publicación
2023
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the infectious agent causing COVID-19 disease, whose pandemic has had far-reaching consequences on the global population. Since the detection of the first cases in late 2019, much has been learned about the mechanism of action of SARS-CoV-2 and the associated immune response to eradicate the infection. Recently, a clear correlation between disease severity and abnormal type I IFN response in patients has been established. Individuals with immune responses characterized by high concentrations of IFN-a2b and low blood levels of IL-6, TNF-alpha, and IL-1Ra were much less affected than those patients who exhibited an opposite scenario. Interestingly, recombinant human IFN-a2b (rhIFN-a2b) could mitigate the severity of symptoms, if given in the early stages of the disease, before reaching the inflammatory shock (cytokine storm) that characterizes the most severe cases. However, there are adverse effects associated with rhIFN-a2b-based therapy. Among them, the emergence of unwanted immune responses against the biologic can, in some cases, compromise the treatment’s safety and efficacy. In addition, rhIFN-a2b is a small cytokine, which results in rapid clearance from the bloodstream. This quick plasma clearance poses the need for frequent high doses to achieve the desired effect, which may, in turn, exacerbate unwanted effects associated with therapy.In this article we will address the most relevant strategies for the development of biobetters versions of rhIFN-a2b, as promising candidates for the treatment of COVID-19 and other human viral diseases.
Fil: Mufarrege, Eduardo Federico. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Cultivos Celulares; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe; Argentina
Fil: Peña, Lucía Carolina. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Cultivos Celulares; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe; Argentina
Fil: Echeverrigaray, Marina. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Cultivos Celulares; Argentina
Materia
SARS-COV-2
COVID-19
IFN-A2B
IMMUNOGENICITY
PEGYLATION
GLYCOSYLATION
BIOBETTER
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/239015
Acceder
id CONICETDig_fde37505ba32697c9d74cf5db98fe835
oai_identifier_str oai:ri.conicet.gov.ar:11336/239015
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Biobetter Versions of Recombinant Human IFN-α2b for the Treatment of Viral InfectionsMufarrege, Eduardo FedericoPeña, Lucía CarolinaEcheverrigaray, MarinaSARS-COV-2COVID-19IFN-A2BIMMUNOGENICITYPEGYLATIONGLYCOSYLATIONBIOBETTERhttps://purl.org/becyt/ford/3.4https://purl.org/becyt/ford/3Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the infectious agent causing COVID-19 disease, whose pandemic has had far-reaching consequences on the global population. Since the detection of the first cases in late 2019, much has been learned about the mechanism of action of SARS-CoV-2 and the associated immune response to eradicate the infection. Recently, a clear correlation between disease severity and abnormal type I IFN response in patients has been established. Individuals with immune responses characterized by high concentrations of IFN-a2b and low blood levels of IL-6, TNF-alpha, and IL-1Ra were much less affected than those patients who exhibited an opposite scenario. Interestingly, recombinant human IFN-a2b (rhIFN-a2b) could mitigate the severity of symptoms, if given in the early stages of the disease, before reaching the inflammatory shock (cytokine storm) that characterizes the most severe cases. However, there are adverse effects associated with rhIFN-a2b-based therapy. Among them, the emergence of unwanted immune responses against the biologic can, in some cases, compromise the treatment’s safety and efficacy. In addition, rhIFN-a2b is a small cytokine, which results in rapid clearance from the bloodstream. This quick plasma clearance poses the need for frequent high doses to achieve the desired effect, which may, in turn, exacerbate unwanted effects associated with therapy.In this article we will address the most relevant strategies for the development of biobetters versions of rhIFN-a2b, as promising candidates for the treatment of COVID-19 and other human viral diseases.Fil: Mufarrege, Eduardo Federico. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Cultivos Celulares; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe; ArgentinaFil: Peña, Lucía Carolina. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Cultivos Celulares; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe; ArgentinaFil: Echeverrigaray, Marina. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Cultivos Celulares; ArgentinaGavin Publishers2023-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/239015Mufarrege, Eduardo Federico; Peña, Lucía Carolina; Echeverrigaray, Marina ; Biobetter Versions of Recombinant Human IFN-α2b for the Treatment of Viral Infections; Gavin Publishers; Infectious Diseases Diagnosis & Treatment; 7; 3; 10-2023; 1-22577-1515CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.29011/2577-1515.100236info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-22T11:44:22Zoai:ri.conicet.gov.ar:11336/239015instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-22 11:44:22.413CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Biobetter Versions of Recombinant Human IFN-α2b for the Treatment of Viral Infections
title Biobetter Versions of Recombinant Human IFN-α2b for the Treatment of Viral Infections
spellingShingle Biobetter Versions of Recombinant Human IFN-α2b for the Treatment of Viral Infections
Mufarrege, Eduardo Federico
SARS-COV-2
COVID-19
IFN-A2B
IMMUNOGENICITY
PEGYLATION
GLYCOSYLATION
BIOBETTER
title_short Biobetter Versions of Recombinant Human IFN-α2b for the Treatment of Viral Infections
title_full Biobetter Versions of Recombinant Human IFN-α2b for the Treatment of Viral Infections
title_fullStr Biobetter Versions of Recombinant Human IFN-α2b for the Treatment of Viral Infections
title_full_unstemmed Biobetter Versions of Recombinant Human IFN-α2b for the Treatment of Viral Infections
title_sort Biobetter Versions of Recombinant Human IFN-α2b for the Treatment of Viral Infections
dc.creator.none.fl_str_mv Mufarrege, Eduardo Federico
Peña, Lucía Carolina
Echeverrigaray, Marina
author Mufarrege, Eduardo Federico
author_facet Mufarrege, Eduardo Federico
Peña, Lucía Carolina
Echeverrigaray, Marina
author_role author
author2 Peña, Lucía Carolina
Echeverrigaray, Marina
author2_role author
author
dc.subject.none.fl_str_mv SARS-COV-2
COVID-19
IFN-A2B
IMMUNOGENICITY
PEGYLATION
GLYCOSYLATION
BIOBETTER
topic SARS-COV-2
COVID-19
IFN-A2B
IMMUNOGENICITY
PEGYLATION
GLYCOSYLATION
BIOBETTER
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.4
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the infectious agent causing COVID-19 disease, whose pandemic has had far-reaching consequences on the global population. Since the detection of the first cases in late 2019, much has been learned about the mechanism of action of SARS-CoV-2 and the associated immune response to eradicate the infection. Recently, a clear correlation between disease severity and abnormal type I IFN response in patients has been established. Individuals with immune responses characterized by high concentrations of IFN-a2b and low blood levels of IL-6, TNF-alpha, and IL-1Ra were much less affected than those patients who exhibited an opposite scenario. Interestingly, recombinant human IFN-a2b (rhIFN-a2b) could mitigate the severity of symptoms, if given in the early stages of the disease, before reaching the inflammatory shock (cytokine storm) that characterizes the most severe cases. However, there are adverse effects associated with rhIFN-a2b-based therapy. Among them, the emergence of unwanted immune responses against the biologic can, in some cases, compromise the treatment’s safety and efficacy. In addition, rhIFN-a2b is a small cytokine, which results in rapid clearance from the bloodstream. This quick plasma clearance poses the need for frequent high doses to achieve the desired effect, which may, in turn, exacerbate unwanted effects associated with therapy.In this article we will address the most relevant strategies for the development of biobetters versions of rhIFN-a2b, as promising candidates for the treatment of COVID-19 and other human viral diseases.
Fil: Mufarrege, Eduardo Federico. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Cultivos Celulares; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe; Argentina
Fil: Peña, Lucía Carolina. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Cultivos Celulares; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Santa Fe; Argentina
Fil: Echeverrigaray, Marina. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Cultivos Celulares; Argentina
description Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the infectious agent causing COVID-19 disease, whose pandemic has had far-reaching consequences on the global population. Since the detection of the first cases in late 2019, much has been learned about the mechanism of action of SARS-CoV-2 and the associated immune response to eradicate the infection. Recently, a clear correlation between disease severity and abnormal type I IFN response in patients has been established. Individuals with immune responses characterized by high concentrations of IFN-a2b and low blood levels of IL-6, TNF-alpha, and IL-1Ra were much less affected than those patients who exhibited an opposite scenario. Interestingly, recombinant human IFN-a2b (rhIFN-a2b) could mitigate the severity of symptoms, if given in the early stages of the disease, before reaching the inflammatory shock (cytokine storm) that characterizes the most severe cases. However, there are adverse effects associated with rhIFN-a2b-based therapy. Among them, the emergence of unwanted immune responses against the biologic can, in some cases, compromise the treatment’s safety and efficacy. In addition, rhIFN-a2b is a small cytokine, which results in rapid clearance from the bloodstream. This quick plasma clearance poses the need for frequent high doses to achieve the desired effect, which may, in turn, exacerbate unwanted effects associated with therapy.In this article we will address the most relevant strategies for the development of biobetters versions of rhIFN-a2b, as promising candidates for the treatment of COVID-19 and other human viral diseases.
publishDate 2023
dc.date.none.fl_str_mv 2023-10
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/239015
Mufarrege, Eduardo Federico; Peña, Lucía Carolina; Echeverrigaray, Marina ; Biobetter Versions of Recombinant Human IFN-α2b for the Treatment of Viral Infections; Gavin Publishers; Infectious Diseases Diagnosis & Treatment; 7; 3; 10-2023; 1-2
2577-1515
CONICET Digital
CONICET
url http://hdl.handle.net/11336/239015
identifier_str_mv Mufarrege, Eduardo Federico; Peña, Lucía Carolina; Echeverrigaray, Marina ; Biobetter Versions of Recombinant Human IFN-α2b for the Treatment of Viral Infections; Gavin Publishers; Infectious Diseases Diagnosis & Treatment; 7; 3; 10-2023; 1-2
2577-1515
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.29011/2577-1515.100236
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Gavin Publishers
publisher.none.fl_str_mv Gavin Publishers
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846782137948176384
score 12.982451

Publicaciones similares